0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Updated Recommendation From the Advisory Committee on Immunization Practices (ACIP) for Use of 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Children Aged 24-59 Months Who Are Not Completely Vaccinated FREE

JAMA. 2008;299(17):2020. doi:10.1001/jama.299.17.2020.
Text Size: A A A
Published online

MMWR. 2008;57:343-344

This notice updates the recommendation for use of 7-valent pneumococcal conjugate vaccine (PCV7) among children aged 24-59 months who are either unvaccinated or who have a lapse in PCV7 administration.* In February 2000, PCV7, marketed as Prevnar® and manufactured by Wyeth Vaccines (Collegeville, Pennsylvania), was approved by the Food and Drug Administration for use in infants and young children. At that time, the Advisory Committee on Immunization Practices (ACIP) recommended that children aged 24-59 months who have certain underlying medical conditions or are immunocompromised receive PCV7. In addition, ACIP recommended that PCV7 be considered for all other children aged 24-59 months, with priority given to those who are American Indian/Alaska Native or of African-American descent, and to children who attend group day care centers.1 The recommendation also provided schedules for administering PCV7 to children aged 24-59 months who were either unvaccinated or who had a lapse in PCV7 administration; these schedules included (1) 1 dose of PCV7 for healthy children, and (2) 2 doses of PCV7 ≥2 months apart for children with certain chronic diseases or immunosuppressive conditions.1

ACIP's rationale for limiting the recommendation for routine vaccination to children aged 24-59 months who have certain underlying medical conditions or are immunocompromised was concern about limited vaccine supply and cost. Since September 2004, PCV7 has not been in short supply.2 Additionally, certain health-care providers have found the permissive recommendation for healthy children aged 24-59 months to be confusing. The ACIP Pneumococcal Vaccines Work Group reviewed data on safety and immunogenicity of PCV7 in children aged 24-59 months, current rates of PCV7-type invasive disease, vaccination coverage rates, and post-licensure vaccine effectiveness. In October 2007, on the basis of that review, ACIP approved the following revised recommendation for use of PCV7 in children aged 24-59 months†:

  • For all healthy children aged 24-59 months who have not completed any recommended schedule for PCV7, administer 1 dose of PCV7.

  • For all children with underlying medical conditions aged 24-59 months who have received 3 doses, administer 1 dose of PCV7.

  • For all children with underlying medical conditions aged 24-59 months who have received <3 doses, administer 2 doses of PCV7 at least 8 weeks apart.

No changes were made to previously published recommendations regarding (1) the use of PCV7 in children aged 2-23 months, (2) the list of underlying medical or immunocompromising conditions, or (3) the use of 23-valent pneumococcal polysaccharide vaccine in children aged ≥2 years who have previously received PCV7.3

REFERENCES

3 Available.

*PCV7 is recommended for routine administration as a 4-dose series for infants at ages 2, 4, 6, and 12-15 months. Catch-up immunization is recommended for children aged ≤23 months, using fewer doses depending on age at the time of first vaccination.

†The minimum interval between all doses of PCV7 for children aged 24-59 months is 8 weeks.

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles